We report a case of metastatic pulmonary calcification in a patient with chronic renal failure on hemodialysis and secondary hyperparathyroidism. The diagnosis was made by using a probe-based confocal endomicroscopy which showed specific structures in the lung tissue and was proven by a transbronchial lung biopsy. To the best of our knowledge, this is the first reported case of the confocal endomicroscopy findings in a patient with metastatic pulmonary calcification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/LBR.0000000000000412 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.
JTO Clin Res Rep
December 2024
Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment.
View Article and Find Full Text PDFPrognostic Value of / Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report.
JTO Clin Res Rep
December 2024
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Introduction: Programmed death-ligand 1 (PD-L1) is the main predictive biomarker used to identify patients with NSCLC who are eligible for treatment with immune checkpoint inhibitors. Despite its utility, the predictive capacity of PD-L1 is limited, necessitating the exploration of supplementary predictive biomarkers. In this report, we describe the prognostic value of / mutation status for overall survival (OS) in patients with NSCLC treated with first-line immunotherapy or combined chemoimmunotherapy.
View Article and Find Full Text PDFHybrid Virtual Coaching and Telemonitoring in COPD Management: The CAir Randomised Controlled Study.
Int J Chron Obstruct Pulmon Dis
December 2024
Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Objective: To investigate the effectiveness of 12-weeks hybrid virtual coaching on health-related quality-of-life (HrQoL) in patients with stable COPD.
Methods: We equipped all patients with a CAir Desk for telemonitoring, the intervention group additionally received hybrid virtual coaching through the built-in smartphone. The multimodal intervention based on the Living well with COPD programme, containing educational content, physical activity coaching, and home-based exercises.
Coexistence of a novel , double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review.
Front Oncol
December 2024
Department of Pathology, China-Janpan Friendship Hospital, Beijing, China.
Background: Anaplastic lymphoma kinase () rearrangement, the most common oncogenic rearrangement in lung adenocarcinoma, occurs in approximately 5% of non-small cell lung cancer (NSCLC) patients. gene is the most common partner of rearrangement, and distinct EML4-ALK fusions differ in their responsiveness to ALK tyrosine kinase inhibitors. However, the concurrence of two rearrangements in one patient and whose response to ALK-TKIs have rarely been reported so far.
View Article and Find Full Text PDFImmunotherapy for lung adenocarcinoma patients with bone metastases: who really needs it.
Front Immunol
December 2024
Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Background: Lung adenocarcinoma patients are often found to have developed bone metastases at the time of initial diagnosis. With the continuous development of technology, we have successfully entered the era of immunotherapy. This study aimed to determine the efficacy of immunotherapy in lung adenocarcinoma patients with bone metastases (LABM) through a multicenter retrospective analysis and to develop a novel tool to identify the population that could benefit most from immunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!